Asset
TAK-733
Recursion Pharmaceuticals Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06005974 | phase2 | terminated | 2024-01-15 | 2025-02-24 | Recursion Pharmaceuticals Inc. | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation |
| NCT05552755 | phase1_2 | recruiting | 2023-07-10 | 2027-06-01 | Recursion Pharmaceuticals Inc. | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) |
FDA applications (0)
This company has no applications containing this asset.